



Dr. Dinah Sah has 19 years of experience in research and drug development in the biotechnology industry, and currently serves as an Independent Biotechnology and Pharmaceutical R&D Consultant. Her accomplishments include leadership of multiple programs from early research through Phase 1 clinical trials, and the discovery of novel therapeutic targets and drug candidates that advanced into clinical development. Most recently, her leadership of multiple research and development programs based on RNAi therapeutics resulted in the landmark demonstration of human proof-of-mechanism for this novel class of drugs in patients. Dr. Sah is an inventor on more than 25 patents, and her publications across diverse research areas include 17 articles in journals such as Nature Medicine, Nature Biotechnology, Nature Neuroscience, Nature Chemical Biology, Nature Reviews Drug Discovery, Molecular Therapeutics, Neuron, PNAS, and EMBO Journal.

Dr. Sah served at Alnylam Pharmaceuticals from 2005 – 2012, where most recently she was Vice President of Research, and provided scientific leadership and administrative oversight of discovery research and multiple research and development programs. Before joining Alnylam, Dr. Sah was Associate Director of Research at Biogen (now Biogen Idec), where she led neuroscience research, strategic planning for the neurobiology focus area, and several research projects. Prior to her 6 years at Biogen, she served at Signal Pharmaceuticals, where she headed neuroscience research and was the leader of multiple corporate partnerships and projects. Dr. Sah received a B.S. in Biology from the Massachusetts Institute of Technology, a Ph.D. in Neurobiology from Harvard University, and her post-doctoral training at Harvard Medical School.